Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 2, 2027

Study Completion Date

December 2, 2028

Conditions
Gastroesophageal Junction Adenocarcinoma
Interventions
RADIATION

Sintilimab combined with chemotherapy and local treatment

"Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable."

COMBINATION_PRODUCT

Sintilimab combined with chemotherapy only

"Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."

Trial Locations (1)

210009

ChengChen, Nanjing

All Listed Sponsors
lead

Jiangsu Cancer Institute & Hospital

OTHER

NCT06739161 - Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ | Biotech Hunter | Biotech Hunter